TKL Research is Building New Clinical Research Facility in Fair Lawn, NJ
TKL Research
, a full-service clinical research organization (
CRO
) with decades of experience in clinical trial management, is constructing a new clinical research facility in Fair Lawn, N.J., that will include a state-of-the-art, 30-bed, Phase 1 unit as well as multiple, outpatient clinical examination rooms.
The new facility, which will also give the company an expanded capability for conducting the full range of dermatological safety studies for which it has a particular expertise, will join three other TKL Research clinics in northern New Jersey as part of the company’s
Research Clinics
Division.
In addition to its leading dermatology capabilities, TKL Research has deep expertise in the areas of gastroenterology, respiratory, endocrinology and women’s health and significant experience in global clinical studies for pharmaceutical, medical device, nutritional and consumer health care companies. The company offers a full range of clinical trial management services, from strategy and protocol development to biostatistics, medical writing and regulatory submission.
“The Fair Lawn research facility will enable us to meet the increased demand for our services in the diseased-state populations for
Phase I clinical trials
in which we have strong patient recruitment expertise,” said TKL Research President and CEO Jon C. Anderson, Ph.D.
The new facility also complements the company’s Clinical Trials Division, based in Rochelle Park, NJ, which provides a full-service capability in the
clinical trial management
of international, multicenter Phase 2-4 studies.
Founded more than 60 years ago, TKL Research moved its CRO operations to Rochelle Park, NJ, in 2006, and expanded its European capabilities with clinical operations in Münster, Germany, in 2010.
“These moves, as well as the construction of our new facility in Fair Lawn, will help us continue to deliver exceptional services to our clients that give them a competitive edge and accelerated enrollment,” Anderson said. “We’re able to work with sponsors and investigators to accelerate enrollment of high-quality study participants, and, through our comprehensive management services, we deliver strong expertise in a comprehensive range of CRO services over a wide geographic area.”
The TKL Research Fair Lawn facility is expected to be operational early next year.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Empower Sponsor Success with Insights from Sites
October 3rd 2024Are you tired of clinical trial technology that slows down processes? Are your sites looking for more intuitive solutions? At YPrime, we’ve taken a deep dive into site experiences and perspectives, sharing ways to bridge the gap between sponsors, sites, and patients, to foster a more efficient clinical trial process.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
New Survey Uncovers Distrust as Key Factor in Enrollment Declines Among Black Patients
October 2nd 2024Findings from two Baltimore medical centers presented at the American Society for Radiation Oncology Annual Meeting suggest spiritual themes and distrust may be behind the decline in trial participation.
Tulisokibart Shows Superior Efficacy in Achieving Clinical Remission for Ulcerative Colitis Patients
October 2nd 2024Proof-of-concept Phase II ARTEMIS-UC trial shows efficacy of investigational humanized monoclonal antibody tulisokibart in treating inflammatory bowel disease compared with placebo.
